

Norbert MÃ¼ller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/791429/publications.pdf>

Version: 2024-02-01

81
papers

4,272
citations

109137

35
h-index

110170

64
g-index

81
all docs

81
docs citations

81
times ranked

4988
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of Association of Group A Streptococcal Infections and Onset of Tics. <i>Neurology</i> , 2022, 98, .	1.5	16
2	Interhelical interactions within the STIM1 CC1 domain modulate CRAC channel activation. <i>Nature Chemical Biology</i> , 2021, 17, 196-204.	3.9	22
3	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. <i>Neurology</i> , 2021, 96, e1680-e1693.	1.5	30
4	Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110226.	2.5	12
5	A role for pathogen risk factors and autoimmunity in encephalitis lethargica?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110276.	2.5	2
6	Resonance assignment of coiled-coil 3 (CC3) domain of human STIM1. <i>Biomolecular NMR Assignments</i> , 2021, 15, 433-439.	0.4	0
7	Brain Versus Blood: A Systematic Review on the Concordance Between Peripheral and Central Kynurenine Pathway Measures in Psychiatric Disorders. <i>Frontiers in Immunology</i> , 2021, 12, 716980.	2.2	32
8	Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline Results From a Randomized Controlled Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 615261.	1.3	10
9	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110391.	2.5	43
10	<i>Mycoplasma pneumoniae</i> IgG positivity is associated with tic severity in chronic tic disorders. <i>Brain, Behavior, and Immunity</i> , 2021, 99, 281-288.	2.0	6
11	Childhood trauma, suicide risk and inflammatory phenotypes of depression: insights from monocyte gene expression. <i>Translational Psychiatry</i> , 2020, 10, 296.	2.4	37
12	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	2.8	36
13	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. <i>Frontiers in Psychiatry</i> , 2019, 10, 458.	1.3	111
14	COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 375.	1.3	81
15	Childhood Adversity and Current Stress are related to Pro- and Anti-inflammatory Cytokines in Major Depression. <i>Journal of Affective Disorders</i> , 2019, 253, 270-276.	2.0	53
16	The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of Psychiatric Disorders. <i>Frontiers in Pharmacology</i> , 2019, 10, 1251.	1.6	103
17	Structural characterization of aerogels derived from enzymatically oxidized galactomannans of fenugreek, sesbania and guar gums. <i>Carbohydrate Polymers</i> , 2019, 207, 510-520.	5.1	22
18	A dual mechanism promotes switching of the Stormorken STIM1 R304W mutant into the activated state. <i>Nature Communications</i> , 2018, 9, 825.	5.8	45

#	ARTICLE	IF	CITATIONS
19	The effect of oxytocin on group formation and strategic thinking in men. <i>Hormones and Behavior</i> , 2018, 100, 100-106.	1.0	5
20	Rapid NMR-scale purification of ¹⁵ N, ¹³ C isotope-labeled recombinant human STIM1 coiled coil fragments. <i>Protein Expression and Purification</i> , 2018, 146, 45-50.	0.6	10
21	Nonlinear detection of secondary isotopic chemical shifts in NMR through spin noise. <i>Nature Communications</i> , 2017, 8, 13914.	5.8	10
22	Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2017, 92, 139-146.	1.5	65
23	Detailed Evidence for an Unparalleled Interaction Mode between Calmodulin and Orai Proteins. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 15755-15759.	7.2	12
24	(<i>Z</i>), Not (<i>E</i>) – An End to a Century of Confusion about the Double-Bond Stereoisomers of α -Amino- α -Cyanoacrylates. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 6408-6412.	1.2	4
25	Silver-, calcium-, and copper molybdate compounds: Preparation, antibacterial activity, and mechanisms. <i>Biointerphases</i> , 2017, 12, 05G607.	0.6	26
26	Oxytocin promotes altruistic punishment. <i>Social Cognitive and Affective Neuroscience</i> , 2017, 12, 1740-1747.	1.5	14
27	High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. <i>Frontiers in Psychiatry</i> , 2017, 8, 16.	1.3	33
28	Neuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation. <i>Modern Problems of Pharmacopsychiatry</i> , 2017, 31, 1-9.	2.5	18
29	Growth inhibition of <i>Escherichia coli</i> by zinc molybdate with different crystalline structures. <i>Physica Status Solidi (A) Applications and Materials Science</i> , 2016, 213, 1471-1478.	0.8	21
30	Use of Nuclear Spin Noise Spectroscopy to Monitor Slow Magnetization Buildup at Millikelvin Temperatures. <i>ChemPhysChem</i> , 2016, 17, 3035-3039.	1.0	6
31	Oxytocin course over pregnancy and postpartum period and the association with postpartum depressive symptoms. <i>Archives of Women's Mental Health</i> , 2016, 19, 571-579.	1.2	54
32	Obsessive-compulsive disorder – A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. <i>Journal of Psychiatric Research</i> , 2015, 68, 354-362.	1.5	22
33	The Role of Inflammation in Alzheimer's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 313-336.	0.4	2
34	Resonance assignment of PsbP: an extrinsic protein from photosystem II of <i>Spinacia oleracea</i> . <i>Biomolecular NMR Assignments</i> , 2015, 9, 341-346.	0.4	3
35	Spin Noise Detection of Nuclear Hyperpolarization at 1.2...K. <i>ChemPhysChem</i> , 2015, 16, 3859-3864.	1.0	8
36	Solution NMR and molecular dynamics reveal a persistent alpha helix within the dynamic region of PsbQ from photosystem II of higher plants. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 1677-1686.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. <i>Acta Neuropsychiatrica</i> , 2014, 26, 347-355.	1.0	72
38	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 190-195.	2.5	10
39	Immunology of Schizophrenia. <i>NeuroImmunoModulation</i> , 2014, 21, 109-116.	0.9	68
40	Empathy in high-tech and high-touch medicine. <i>Patient Education and Counseling</i> , 2014, 95, 259-264.	1.0	17
41	Immunology of Major Depression. <i>NeuroImmunoModulation</i> , 2014, 21, 123-130.	0.9	136
42	Facility based cross-sectional study of self stigma among people with mental illness: towards patient empowerment approach. <i>International Journal of Mental Health Systems</i> , 2013, 7, 21.	1.1	42
43	Anti-inflammatory treatment in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 146-153.	2.5	77
44	Emotional and Cognitive Empathy in First-Year Medical Students. , 2013, 2013, 1-6.		20
45	The role of anti-inflammatory treatment in psychiatric disorders. <i>Psychiatria Danubina</i> , 2013, 25, 292-8.	0.2	52
46	Infectious agents are associated with psychiatric diseases. <i>Mental Illness</i> , 2012, 4, 38-42.	0.8	9
47	Inflammation in Schizophrenia. <i>Advances in Protein Chemistry and Structural Biology</i> , 2012, 88, 49-68.	1.0	76
48	Impaired monocyte activation in schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 341-346.	1.7	72
49	Immunological Treatment Options for Schizophrenia. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1606-1613.	0.9	26
50	Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now?. <i>Journal of Psychopharmacology</i> , 2011, 25, 713-714.	2.0	23
51	Attentional modulation of external speech attribution in patients with hallucinations and delusions. <i>Neuropsychologia</i> , 2011, 49, 805-812.	0.7	22
52	Inflammatory Biomarkers and Depression. <i>Neurotoxicity Research</i> , 2011, 19, 308-318.	1.3	106
53	Inside Cover: Tight Binding of Transition-State Analogues to a Peptidyl-Aminoacyl-L/D-Isomerase from Frog Skin (<i>ChemBioChem</i> 13/2011). <i>ChemBioChem</i> , 2011, 12, 1942-1942.	1.3	0
54	Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects. <i>Current Pharmaceutical Design</i> , 2011, 17, 130-136.	0.9	80

#	ARTICLE	IF	CITATIONS
55	Neuroinflammation, Microglia and Implications for Anti-Inflammatory Treatment in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-9.	1.1	93
56	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. <i>Schizophrenia Research</i> , 2010, 121, 118-124.	1.1	227
57	COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 31-42.	2.3	67
58	The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders—relation to drug treatment. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 319-332.	1.8	64
59	A psychoneuroimmunological perspective to Emil Kraepelin's dichotomy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 97-106.	1.8	111
60	Duloxetine in the treatment of major psychiatric and neuropathic disorders. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 527-536.	1.4	184
61	Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1497-1507.	1.5	34
62	COX-2 Inhibition in Schizophrenia and Major Depression. <i>Current Pharmaceutical Design</i> , 2008, 14, 1452-1465.	0.9	94
63	Coherence pathway selection by cogwheel phase cycling in liquid-state NMR. <i>Concepts in Magnetic Resonance Part A: Bridging Education and Research</i> , 2007, 30A, 81-99.	0.2	10
64	Significant alterations in peripheral blood lymphocyte subsets in patients with somatoform disorder. <i>Acta Neuropsychiatrica</i> , 2007, 19, 368-375.	1.0	2
65	Pragmatic Studies on Protein-Resistant Self-Assembled Monolayers. <i>Monatshefte für Chemie</i> , 2007, 138, 245-252.	0.9	7
66	Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches.. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 161-171.	1.8	28
67	Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1017-1038.	1.4	59
68	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. <i>Neurotoxicity Research</i> , 2006, 10, 131-148.	1.3	205
69	Nuclear spin noise imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6790-6792.	3.3	62
70	Clinical effects of COX-2 inhibitors on cognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 149-151.	1.8	118
71	Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome. <i>Inflammopharmacology</i> , 2004, 12, 271-275.	1.9	12
72	COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 14-22.	1.8	126

#	ARTICLE	IF	CITATIONS
73	A Novel Route to trans -Epoxidation of Terpinen-4-ol. Monatshefte für Chemie, 2004, 135, 35-40.	0.9	4
74	Base-Catalysed Hydrolysis and Reactivity-Spectra Correlations of (Z)-4-Benzylidene-2-(Substituted) Thiopyranones. Tetrahedron Letters, 2004, 35, 101-104.	0.6	2
75	Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia. American Journal of Psychiatry, 2002, 159, 1029-1034.	4.0	366
76	Comorbidity of Tourette's syndrome and schizophrenia – biological and physiological parallels. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1245-1252.	2.5	22
77	Increased anti-streptococcal antibodies in patients with Tourette's syndrome. Psychiatry Research, 2000, 94, 43-49.	1.7	69
78	Cellular and Humoral Immune System in Schizophrenia: A Conceptual Re-Evaluation. World Journal of Biological Psychiatry, 2000, 1, 173-179.	1.3	79
79	The Immune System and Schizophrenia: An Integrative View. Annals of the New York Academy of Sciences, 2000, 917, 456-467.	1.8	161
80	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neuroscience Letters, 1999, 259, 145-148.	1.0	56
81	Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 308-313.	1.8	124